Background: Bloodstream infections (BSIs) caused by enterobacteria remain a leading cause of mortality in patients with chemotherapy-induced neutropenia. The rate and type of colonization and infection with ESBLproducing Enterobacteriaceae (ESBL-E) and their mode of transmission in German cancer centres is largely unknown.
Introduction
Bloodstream infections (BSIs) remain the leading cause of mortality in patients with chemotherapy-induced neutropenia.
1,2 A relevant number of these BSIs originate from bacterial penetration of the impaired mucosal barrier during neutropenia. 3 -5 This origin of BSIs might be gaining further importance, as the global spread of multidrug-resistant (MDR) bacteria is becoming a matter of increasing concern. 6 -8 Gut colonization with MDR bacteria may subsequently evolve into BSI after administration of chemotherapy. In the setting of febrile neutropenia, BSI with ESBL-producing Enterobacteriaceae (ESBL-E) represents a particular challenge.
Concerning empirical treatment of febrile neutropenia, it has been proposed that patients treated at centres with high rates of colonization with ESBL-E may benefit from faecal screening in combination with targeted empirical carbapenem treatment. 9 However, this question has not been assessed in a structured fashion and the establishment of faecal screening as a standard of care is based on expert opinion only.
Similarly, infection control measures for patients infected or colonized with ESBL-E are the subject of debate, particularly the need for contact isolation. The German commission KRINKO (Kommission fü r Krankenhaushygiene und Infektionsprä vention) recommends contact isolation for patients infected or colonized with fluoroquinolone-resistant ESBL-E in high-risk settings, e.g. haematology/oncology wards and ICUs. 10 In contrast to this statement, ESCMID recommends these precautions for carriers of ESBL-producing Klebsiella pneumoniae and for any ESBL-E outbreak setting only. In an endemic setting, there is only a conditional recommendation for contact isolation of carriers of ESBL-producing Escherichia coli, even in high-risk settings. 11 While infection control measures have a significant impact on patient care, their development and implementation is often hampered by the lack of reliable clinical data.
This problem is further complicated by regional differences in the evolution of ESBL-E, both in the community and in the hospital setting. Large surveillance networks such as EARS-Net (European Antimicrobial Resistance Surveillance Network) 12 or SMART (Study for Monitoring Antimicrobial Resistance Trends) 13 provide highly valuable data on resistance trends at a national and international level. However, conclusions on local resistance rates in selected patient populations cannot be drawn from these sources. Detailed epidemiological information at the patient level is indispensable to the design of any interventional study.
To improve epidemiological knowledge on ESBL-E in German haematological high-risk patients and thus facilitate the design of further interventional studies, a prospective multicentre study was performed to assess: (i) the rate of intestinal colonization with ESBL-E at hospital admission and during the course of hospitalization; (ii) the rate of patient-to-patient transmission of ESBL-E; (iii) the rate of BSIs with ESBL-E; and (iv) risk factors for the occurrence of BSIs with ESBL-E.
Methods

Setting
This study was conducted at five German university-based haematology/ oncology departments. All departments had already implemented routine faecal screening for intestinal colonization with ESBL-E into their standard of care at the time of study initiation. Screening protocols included collection of a stool sample or rectal swab within 72 h of admission. At four of the five centres (A -D), additional samples were collected every 10+2 days and within 72 h before discharge from hospital. At Centre E, follow-up samples were not part of the local standard of care. Readmitted patients were screened upon each new admission. At Centre A, patients colonized or infected with ESBL-E were placed into single-room contact isolation only if they had urinary or faecal incontinence or diarrhoea (more than three unformed stools within 24 h). At Centre B, only carriers of fluoroquinolone-resistant ESBL-E were placed into single-room contact isolation, irrespective of showing signs of incontinence. The remaining centres (C -E) followed a policy of single-room contact isolation for all patients colonized or infected with any kind of ESBL-E at all times. At all centres, cohorting of ESBL-E-colonized or -infected patients was only practised if no single rooms were available. As a standard of care at all participating sites, two blood culture sets were drawn in patients with neutropenic fever or suspicion of BSI.
Study design
The present study was designed as a prospective, observational multicentre study, assessing the period from 1 October 2011 to 31 December 2012. All hospitalizations of high-risk patients admitted during this period were eligible for documentation in the study. Patients receiving one of the following cytotoxic treatments were considered high risk: (i) induction and consolidation chemotherapy for AML or ALL; (ii) high-dose chemotherapy with consecutive autologous stem cell transplantation (SCT); or (iii) conditioning chemotherapy with consecutive allogeneic SCT.
Intestinal colonization with ESBL-E was defined as detection of ESBL-E in at least one stool sample or rectal swab. BSI due to ESBL-E was defined as ESBL-E recovered from at least one blood culture. A patient was considered no longer colonized when two consecutive stool cultures or rectal swabs collected at a maximum interval of 3 weeks no longer yielded ESBL-E.
For determination of nosocomial colonization (NC) as opposed to community-acquired colonization (CAC), only patients whose first admission to a study site fell into the study period and from whom subsequent screening samples during the same hospitalization had been obtained were considered eligible for analysis. Since follow-up samples were not a standard of care at Centre E, patients from this centre were not included in this subanalysis. If consecutive screening samples from the same patient and hospital stay revealed a switch from a negative to a positive carrier status, this was considered NC. If a patient presented with a positive admission screening or if he changed his carrier status from negative to positive between two hospitalizations, this was considered CAC.
Anonymized data of eligible patients were entered into web-based electronic case report forms (eCRFs).
14 A search of the literature was carried out to identify potential risk factors for ESBL-E BSIs. 9, 15, 16 Documentation included age, gender, weight, height, underlying disease requiring chemotherapy, duration of hospital stay, information on allogeneic or autologous SCT and result and type of screening samples. If a screening sample or a blood culture positive for ESBL-E was entered into the eCRF, documentation was extended to include the following items: type of administered antimicrobial and chemotherapy agents; ICU treatment; total parenteral nutrition; haemodialysis; central venous catheter; neutropenia; and death. An intention-to-treat approach was used for inclusion of these variables in the analysis, considering a single dose/day relevant for the analysis. In case of a blood culture positive for ESBL-E, information on the type and duration of antimicrobial treatment, removal of central venous catheters and treatment outcome was documented as well. The documentation of each hospitalization ended with the day of discharge or death, whichever occurred first.
In addition, all participating centres received a questionnaire to assess current infection control standards concerning ESBL-E colonization and infection.
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Statistical analysis
All statistical analyses were carried out using SPSS software (IBM SPSS Statistics, version 21; IBM, Armonk, NY, USA). We performed descriptive statistics as appropriate to evaluate the dataset. All risk factors identified during the literature search (see the Study design section) were first analysed using univariate statistics (Student's t-test for continuous variables and Fisher's exact test for dichotomous variables). To assess the independence of covariates, we performed binary logistic regression with occurrence of BSI as the dependent variable and potential risk factors as covariates. We then eliminated covariates from the analysis by a stepwise, backward approach, using Wald's statistic with an exclusion margin of 0.1 to improve the model further. For multivariate analysis, we aggregated sequential hospitalizations of the same patient into a single dataset. For all analyses, a P value ,0.05 was considered significant.
Microbiological analysis
Stool and blood specimens were processed at the local microbiology departments in accordance with 'Microbiology Procedures Quality Standards (MiQ)' issued by the German Society for Hygiene and Microbiology. 17 Chromogenic culture media were used in addition to non-selective, non-chromogenic media to improve the detection of ESBL-E. Species identification and susceptibility testing including confirmatory tests for ESBL identification were performed using Vitek 2 (bioMé rieux, Nü rtingen, Germany) or a linear MALDI-TOF mass spectrometer (bioMérieux, Marcy-l'Étoile, France or Bruker Daltonic, Bremen, Germany) according to CLSI or EUCAST standards. 18, 19 ESBL production was confirmed with the CLSI combination disc test where appropriate.
All E. coli and K. pneumoniae ESBL-E isolates, including those obtained from multiple screenings, were typed by repetitive extragenic palindromic PCR (rep-PCR) using the DiversiLab platform (bioMérieux) as described elsewhere. 20 To maximize discrimination, E. coli and K. pneumoniae isolates with similar rep-PCR patterns (.95% similarity) as well as isolate pairs from stool and blood in a given patient were also typed by PFGE and interpreted as described elsewhere. 21 
Ethical considerations
Approval of the local Ethics Committee was obtained at all participating sites.
Results
Demographics
Between October 2011 and December 2012, 719 hospitalizations of 497 patients and 20 143 patient-days were entered into the database (mean duration of hospitalization: 36.6 days; range: 2 -159 days). There were no missing data. A total of 311 patients (62.6%) received intensive chemotherapy for acute leukaemia; 107 patients (21.5%) underwent autologous SCT and 223 (44.9%) allogeneic SCT. Three patients received two sequential autologous SCTs and nine patients two sequential allogeneic SCTs. Two patients received an autologous SCT followed by an allogeneic SCT. Table 1 summarizes the patient demographics.
Colonization and transmission
Overall, 1931 screening samples were obtained. The distribution of patients, hospitalizations and samples by centre is shown in Table 2 . Overall, 163 screening samples positive for ESBL-E were obtained [i.e. E. coli, 135 isolates (82.8%); K. pneumoniae, 24 isolates (14.6%); Klebsiella oxytoca, 2 isolates (1.2%); and Enterobacter cloacae, 2 isolates (1.2%)]. These isolates were detected in samples from 55/497 patients (11.1%; range by centre: 5.8%-23.1%). The distribution of colonization with different ESBL-E species was E. coli in 49 patients (89.1%), K. pneumoniae in 2 patients (3.6%), K. oxytoca in 2 patients (3.6%) and E. cloacae in 1 patient (1.8%). Two patients experienced simultaneous colonization with ESBL-producing E. coli and K. oxytoca (3.6%) and one patient with ESBL-producing E. coli and K. pneumoniae (1.8%). Table 1 shows the demographic details of patients with intestinal colonization with ESBL-E.
Overall, 26/55 (47.2%) patients colonized with ESBL-E were eligible for analysis of their origin of colonization. Based on this analysis, CAC and NC occurred in 15/26 (57.7%; E. coli only) and 11/26 (42.3%; E. coli ¼ 9, E. cloacae ¼ 1 and K. oxytoca ¼ 1) patients, respectively. The rate of NC with ESBL-E was low at all centres included in the analysis (A, 1.1 cases per 1000 patient-days; B, 1.4 cases per 1000 patient-days; C, 1.3 cases per 1000 patientdays; and D, 0.54 cases per 1000 patient-days). To further assess ESBL-producing Enterobacteriaceae in haematological high-risk patients potential nosocomial patient-to-patient transmission, molecular epidemiologic analyses of ESBL-E isolates of all colonized and infected patients (E. coli, 49 patients; and Klebsiella spp., 8 patients) was carried out and revealed only a single case of potential cross-transmission between two patients colonized with K. pneumoniae; however, these patients were not hospitalized simultaneously. Two isolates of patients colonized with E. coli were missing and could not be included in this analysis. Twenty-two of the 55 patients (40.0%) colonized with ESBL-E converted to a negative ESBL-E carrier status during the study period. Among these 22 patients, 18 (81.8%) maintained this status until their last documented observation; in 3 patients (13.6%), ESBL-E were again isolated from subsequent screening samples. To assess potential factors responsible for successful decolonization, previously administered antimicrobials with activity against ESBL-E were analysed. Before conversion to a negative carrier status, 13 patients (59.1%) had received treatment with a carbapenem, 11 with a fluoroquinolone (50.0%) and 2 (9.1%) with an aminoglycoside. There was no significant change in the colonization rate over the study period.
BSIs
Six episodes of BSI with ESBL-E (E. coli, 4; K. pneumoniae, 1; and E. cloacae, 1) were detected in 5/497 patients (1.0%) accounting for 6/719 hospitalizations (0.8%). Four of the five patients with BSIs belonged to the group of 55 patients that had been previously found to be colonized with ESBL-E, while the other patient belonged to the group of 442 patients not colonized with ESBL-E (P ¼ 0.0006, Fisher's exact test). In all four cases, the bacteria isolated from blood cultures were identical to the colonizing isolate as assessed by PFGE. Multivariate analysis revealed previous colonization with ESBL-E as the most important risk factor for BSI with ESBL-E, with an associated OR of 52.00 (95% CI 5.71 -473.89). Detailed results of the univariate and multivariate analyses are shown in Table 3 .
Patients with BSI due to ESBL-E were treated with carbapenems (n ¼ 5 episodes) and a fluoroquinolone (n ¼ 1 episode), respectively. In the patient in whom a fluoroquinolone was used, the isolate tested susceptible. The mean time to treatment initiation was 1.3 days (range: 0 -4 days). During five of the six corresponding hospitalizations, a central venous catheter had been placed and was removed after detection of ESBL-E from blood cultures in four patients. After onset of BSI due to ESBL-E, one patient required transfer to the ICU, but there were no fatalities. No other invasive infections due to ESBL-E were observed during the study period.
Discussion
Our study demonstrates that BSI with ESBL-E was a rare event in a high-risk population with haematological malignancies in Germany. However, the rate of intestinal colonization with ESBL-E varied considerably between centres and was as high as 23%.
Epidemiological analysis yielded 11 cases of NC. In the interpretation of this figure, it should be considered that a case of NC as defined here is not necessarily the result of in-hospital transmission. Low-level colonization on admission may have gone undetected using our culture-based protocol. It may, however, have become apparent once bacterial density increased under the selective pressure exerted by antimicrobial treatment for febrile neutropenia.
Furthermore, it is noteworthy that the estimated NC rate was not only low (range: 0.54 -1.4 cases per 1000 patient-days), but also independent of enforcement of contact isolation. This finding Vehreschild et al.
touches on an issue of substantial practical and economic relevance. While ESBL-E colonization and infection is being perceived as an emerging healthcare problem, interventional studies on the effect of infection control measures, including contact isolation, are lacking. The issue is further complicated by contradictory recommendations on the management of patients with ESBL-E. While the German KRINKO recommends contact isolation for patients colonized or infected with fluoroquinolone-resistant ESBL-E in high-risk settings, such as haematology/oncology wards and ICUs, 10 the ESCMID guidelines distinguish between different species of Enterobacteriaceae. For ESBL-producing Klebsiella spp., their recommendation is identical to the directive of the KRINKO. However, no recommendation for contact precautions was made for patients colonized with ESBL-producing E. coli in non-epidemic settings.
11 Considering the relevance of K. pneumoniae as a cause of nosocomial outbreaks, 22 a cautious approach towards this organism seems warranted. However, in line with our findings, patient-to-patient transmission of ESBL-producing E. coli has been reported to be low in other studies. Fankhauser et al. 23 reported that among 177 patients sharing a room with a carrier of ESBL-producing E. coli, 5 (2.8%) acquired the identical strain. Tschudin-Sutter et al. 24 found only two transmission events among 133 room-mates (1.5%) of patients colonized with ESBL-producing E. coli. Furthermore, the evidence pointing towards primarily community acquisition of ESBL-producing E. coli is increasing. In particular, poultry has been identified as a potential reservoir. 25 In addition, given the potentially detrimental effects of contact isolation for .48 h, i.e. electrolyte disorders, a decrease in scores for self-esteem and an increase in scores for anxiety and depression, 26 a randomized clinical trial assessing the efficacy of contact isolation is clearly needed.
Using logistic regression, we aimed to identify patients at high risk of developing BSI with ESBL-E. Intestinal colonization with ESBL-E was identified as the most relevant risk factor, with an associated OR of 52.00. At all centres, only those patients known to be colonized with ESBL-E received empirical antimicrobial treatment with a carbapenem as standard of care in the event of febrile neutropenia. First-line treatment strategies for other patients were piperacillin/tazobactam, ceftriaxone and ceftazidime, all with or without gentamicin. This strategy of adapted empirical treatment may help to decrease the consumption of carbapenems and thus reduce selection pressure. The effort and cost associated with this strategy is, however, considerable. While hospitals with a high incidence of ESBL-E may benefit from its implementation, low incidence sites are likely to achieve only a limited clinical benefit at a considerable cost.
Finally, this study has several limitations. Only recently, Tschudin-Sutter et al.
27 assessed colonization patterns of 133 patients carrying ESBL-E and found 24.1% of these patients to have lower urinary tract colonization only. However, urine samples were not included in our screening protocol. Therefore, our study might have underestimated the true rate of colonization with ESBL-E. Furthermore, screening of faecal samples harbours many potential pitfalls. While stool samples naturally produce a high yield of organisms, they are not always readily available. Timing is less of an issue when using rectal swabs; however, their diagnostic yield can be variable, in particular if a perianal swab as opposed to a deep rectal swab was obtained. Inclusion of perianal swabs could have resulted in an underestimation of the rate of ESBL-E colonization. Therefore, the definition for classification of previous carriers into non-carriers should be discussed. This transition was considered to have occurred once two consecutive stool cultures or rectal swabs no longer yielding ESBL-E were documented. While this definition has been applied in previous analyses, 9, 28, 29 it should be considered a compromise between maximum feasibility and specificity. Based on this definition, three of the patients that converted to a negative carrier status were subsequently found to be colonized with the same ESBL-producing isolate. In these patients, low-level colonization may have impeded detection in the first two negative screening samples. While three consecutive results would certainly have improved specificity, feasibility would have been compromised due to a higher likelihood of discharge before completion of the sample series. The rate of observed ESBL-E BSIs was comparably low, leading to broad CIs for the observed OR in the multivariate analysis of risk factors. Finally, continuous training and monitoring of all parties involved in the process of screening was performed at all participating centres. However, these efforts were not documented in a standardized fashion to serve as an objective marker of quality control.
We conclude that the present study provides the first structured analysis on incidence rates of colonization with ESBL-E in German haematology/oncology high-risk patients. Rates of colonization and infection with ESBL-E varied considerably between study sites. While our data may support screening in highincidence settings, the cost-benefit ratio may not be satisfactory in a low-incidence setting. Our findings support previous reports on predominantly community acquisition of colonization with ESBL-producing E. coli and there was no clear evidence of inhospital transmission as assessed by molecular epidemiological methods. Our observation that ESBL-E were not spread between patients even in centres performing contact isolation only in a minority of patients suggests a low impact of contact isolation on ESBL-E spread, even in a high-risk hospital setting. To further assess this hypothesis, we propose the conduct of a randomized multicentre clinical trial.
